Magenta Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Dianthus Therapeutics

03/11/2022 14:10

* Magenta Therapeutics Inc  MGTA.OQ  reported a quarterly
adjusted
loss of 27 cents​​ per share for the quarter ended in September.
The mean expectation of five analysts for the quarter was for a
loss of 30 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Magenta Therapeutics Inc's reported EPS for the quarter
was a
loss of 27 cents​.
    * The mean earnings estimate of analysts had fallen by
about 5.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Magenta Therapeutics Inc shares had fallen by 12.8% this
quarter and lost 72.2% so far this year.
    * The company reported a quarterly loss of $16.06 million.
    * Wall Street's median 12-month price target for Magenta
Therapeutics Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
3 at 02:09 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.30          -0.27          Beat
 Jun. 30 2022      -0.33          -0.29          Beat
 Mar. 31 2022      -0.31          -0.39          Missed
 Dec. 31 2021      -0.32          -0.33          Missed